

Therapie der Lebererkrankungen

Bericht vom 8. Postgraduierntenkurs der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, 12.09.2001 in Münster

**Beitrag von P. Stiefelhagen (2002)
Der Internist 43:294-299**

Bei obigem Beitrag unterlief leider ein Fehler in der Quellenzitierung der Abbildungen der Falk Foundation e.V. Abbildung 1 stammt von Professor Rasenack, Freiburg, die Abbildungen 2 und 3 von Professor Eisenburg, München, und Abbildung 4 stammt von Professor Ochs, Freiburg. Wir bitten diesen Irrtum zu entschuldigen.

25. Hehlmann R, Hochhaus A, Kolb HJ et al. for the German CML-Study Group and the SAKK (1999) Interferon before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. *Blood* 94: 3668–3677
26. Hochhaus A, Kreil S, Corbin A et al. (2001) Roots of clinical resistance to STI-571 cancer therapy. *Science* 293: 2163a
27. Hochhaus A, Reiter A, Saußele S et al. for the German CML Study Group and the U.K.MRC CML Study Group (2000) Molecular heterogeneity in complete cytogenetic responders after interferon- α therapy for chronic myeloid leukemia: low levels of minimal residual disease are associated with continuing remission. *Blood* 95: 62–66
28. Hochhaus A, Weisser A, La Rosée P et al. (2000) Detection and quantification of residual disease in chronic myelogenous leukemia. *Leukemia* 14: 998–1005
29. Kantarjian H, Sawyers C, Hochhaus A et al. on behalf of the International STI571 CML Study Group (2002) Imatinib mesylate (Gleevec™) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study. *N Engl J Med* 346: 645–652
30. Kantarjian HM, Vellekoop L, McCredie KB et al. (1985) Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. *J Clin Oncol* 3: 192–200
31. Kreil S, Müller MC, Lahaye T et al. (2001) Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. *Blood* 98 (Suppl): 435a
32. La Rosée P, O'Dwyer ME, Druker BJ (2002) Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec™/Glivec®) in chronic myelogenous leukemia: a translational perspective. *Leukemia* 16: (in press)
33. McSweeney PA, Niederwieser D, Shizuru JA et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. *Blood*. 97: 3390–3400
34. Nagler A, Slavin S, Naparstek E, Samuel S, Or R (2000) Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. *Bone Marrow Transplant* 25: 1021–1028
35. O'Brien S, Kantarjian H, Koller C et al. (1999) Sequential homoharringtonine and interferon- α in the treatment of early chronic phase chronic myelogenous leukemia. *Blood* 93: 4149–4153
36. Reiter A, Hochhaus A, Berger U, Kuhn C, Hehlmann R (2001) AraC-based pharmacotherapy of chronic myeloid leukaemia. *Expert Opin Pharmacother* 2: 1129–1135
37. Rushing D, Goldman A, Gibbs G, Howe R, Kennedy BJ (1982) Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. *Am J Clin Oncol* 5: 307–313
38. Sawyers CL, Hochhaus A, Feldman E et al. (2002) Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. *Blood* 99: 3530–3539
39. Schoch C, Schnittger S, Bursch S et al. (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. *Leukemia* 16: 53–59
40. Silver RT, Woolf SH, Hehlmann R et al. (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. *Blood* 94: 1517–1536
41. Simonsson B, Oberg G, Bjoreman M et al. for the Danish-Swedish CML group (1996) Intensive treatment in order to minimize the Ph-positive clone in CML. *Bone Marrow Transplant* 17 (Suppl): S63–S64
42. Talpaz M, O'Brien S, Rose E et al. (2001) Phase 1 study of polyethylene glycol formulation of interferon α -2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. *Blood* 98: 1708–1713
43. Talpaz M, Silver RT, Druker BJ et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase II study. *Blood* 99: 1928–1937
44. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. *N Engl J Med* 330: 820–825
45. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1998) Long-term follow-up of the Italian trial of interferon- α versus conventional chemotherapy in chronic myeloid leukemia. *Blood* 92: 1541–1548